[
    [
        {
            "time": "",
            "original_text": "高瓴百亿重仓的“卖铲子”行业，干的是医药界富士康的生意？",
            "features": {
                "keywords": [
                    "高瓴",
                    "重仓",
                    "医药",
                    "富士康",
                    "卖铲子"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "高瓴百亿重仓的“卖铲子”行业，干的是医药界富士康的生意？",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业点评报告：ASCO 2020全球进展解读：免疫疗法依旧亮眼 联合用药大势所趋",
            "features": {
                "keywords": [
                    "医药生物",
                    "ASCO",
                    "免疫疗法",
                    "联合用药",
                    "全球进展"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业点评报告：ASCO 2020全球进展解读：免疫疗法依旧亮眼 联合用药大势所趋",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业投资策略月报：布局高景气度细分领域 聚焦业绩持续增长带来的机会",
            "features": {
                "keywords": [
                    "医药生物",
                    "投资策略",
                    "高景气度",
                    "细分领域",
                    "业绩增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业投资策略月报：布局高景气度细分领域 聚焦业绩持续增长带来的机会",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]